Spatial Biology

Spatial biology utilizes a suite of technologies for studying high-plex biomarker expression directly within the native spatial context of intact tissues. Unlike traditional bulk or standard single-cell omics platforms that lose spatial information from tissue dissociation, these newer methods preserve the complex architecture of tissue microenvironments. Spatial biology techniques allow researchers to visualize and quantify thousands of RNA and protein targets with single-cell or even subcellular resolution. This approach is particularly significant because it enables a deeper understanding of tissue heterogeneity, cellular neighborhoods, and critical cell-cell interactions that drive biological processes. Spatial biology is advancing research across diverse fields, including oncology, neuroscience, and cardiovascular diseases, by providing a unified molecular view of both healthy and diseased states. It also supports drug discovery and development by facilitating the identification of novel biomarkers and therapeutic targets for complex diseases. As these tools become more robust and accessible, they hold the potential to revolutionize personalized medicine and our fundamental understanding of human biology.

Next-Generation Sequencing (NGS)-based spatial omics platforms utilize barcoded oligonucleotide probes to quantify high-plex biomarker expression while preserving the physical organization of cells within a tissue. One prominent category includes array-based methods like Visium and Slide-seq, which capture mRNA using slides or beads covered in spatially indexed primers to map gene expression across a surface. Another is Digital Spatial Profiling (DSP), which employs UV-photocleavable tags to enable scalable, morphology-guided whole transcriptome analysis from distinct tissue regions selected by a researcher. Additionally, microfluidic barcoding platforms such as DBiT-seq use deterministic barcoding through microchannels to co-profile RNA, proteins, and epigenetic features like chromatin accessibility on the same tissue section. While resolution varies across these platforms from 55-µm spots to near single-cell levels, newer "tag donation" models are emerging that transfer barcodes directly into intact nuclei. This innovative "beam-me-up" approach is significant because it establishes spatial data before cell lysis, potentially eliminating the need for complex deconvolution or cell segmentation algorithms. Collectively, these NGS-driven tools are revolutionizing biomarker discovery by providing deep molecular insights into cellular neighborhoods and interactions in diseases like cancer and heart failure.

Fluorescence-based multiplexed imaging utilizes fluorophore-labeled antibodies or oligonucleotide probes to visualize and quantify various biomarkers within a single tissue section. While traditional methods were limited by spectral overlap, modern techniques employ iterative cycles of staining and dye inactivation to detect dozens of protein markers on a slide. Protein-focused platforms like Cell DIVE enable high-plex, whole-slide imaging of over 60 biomarkers, which can be further enhanced by AI-powered image analysis software. In contrast, transcriptomic-based approaches like MERFISH and seqFISH+ utilize error-robust binary barcoding to map the spatial distribution of thousands of RNA species at subcellular resolution. These advanced imaging tools are critical for identifying rare cell types and characterizing complex neighborhoods where specific cellular interactions drive disease progression. Current innovations also allow for the integration of multi-omic data, enabling researchers to examine gene expression and protein translation simultaneously within intact tissue architecture.

Mass spectrometry-based imaging offers a powerful alternative to fluorescence for spatial analysis, capturing complex molecular data while maintaining tissue architecture. Advanced platforms like Imaging Mass Cytometry (IMC) and Multiplex Ion Beam Imaging (MIBI) utilize antibodies tagged with rare-earth metal isotopes to identify dozens of targets simultaneously. This metal-based detection is significant because it avoids common imaging issues such as spectral overlap and tissue autofluorescence, enabling high-quality data at subcellular resolution. Beyond protein detection, techniques like MALDI-MSI allow for the direct spatial mapping of metabolites and lipids without the need for specific probes. Another cutting-edge approach, Deep Visual Proteomics (DVP), integrates high-resolution microscopy and AI-guided laser microdissection with ultra-sensitive LC-MS to profile thousands of proteins from specific cell populations. These MS-based tools are particularly valuable for identifying proteoforms and post-translational modifications that traditional transcriptomic methods cannot detect. Consequently, mass spectrometry imaging is driving breakthroughs in diverse areas, including metabolic mapping in kidney repair and understanding the complex immune landscape of atherosclerotic plaques.